Vaccination against papillomavirus in cattle

Clinics in Dermatology

Volumn 15, Issue 2, 1997, Pages 275-283

  Campo, M Saveria ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CAPSID PROTEIN; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CATTLE; CONTROLLED STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PAPILLOMA VIRUS; PAPILLOMATOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; REVIEW; VACCINATION; VIRUS PARTICLE;

EID: 0030905593     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00165-4     Document Type: Article

References (52)

1. zur Hausen H. Viruses in human cancer. Science 1991;254: 1167-73.
2. Wild CP, Jansen LAM, Cova L, et al. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial aetiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993;99:115-22.
3. Munoz N, Bosch FX, Shah KV, et al, editors. The epidemiology of human papillomavirus and cervical cancer. Vol. 119. Lyon: IARC Scientific Publications, 1992.
4. Chen D-S. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-70.
5. Frazer IH, Tindle RW. Cell-mediated immunity to papillomavirus. Papillomavirus Rep 1992;3:53-58.
6. Shope RE. Immunization of rabbits to infectious papillomatosis. J Exp Med 1937;65:219-31.
7. van Rast MA, Tachezy R, Delius H, et al. Taxonomy of the human papillomaviruses. Papillomavirus Rep 1993;4: 61-5.
8. Rose RC, Bonnez W, Da Rin C, et al. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 1994;75: 2445-9.
9. Holinger PH, Shiprowitz NL, Holper JC, et al. Studies of etiology of laryngeal papilloma and an autogenous laryngeal papilloma vaccine. Acta Oto-laryngol (Stockh) 1968; 65:63-9.
10. Powell LC, Pollard M, Jinkins JL. Treatment of condylomata acuminata by autogenous vaccine. South Med J 1970;63:202-5.
11. Jarrett WFH, O'Neil BW, Gaukroger JM, et al. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extracts and transformed cells in prophylactic vaccination. Vet Rec 1990;126:450-3.
12. Jarrett WFH, O'Neil BW, Gaukroger JM, et al. Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 1990;126:483-5.
13. Jarrett WFH, Smith KT, O'Neil BW, et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991;184:33-42.
14. Campo MS, Grindlay GJ, O'Neil BW, et al. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993;74:945-53.
15. Chandrachud LM, Grindlay GJ, McGarvie GM, et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus type 4. Virology 1995;211:204-8.
16. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;218: 37-44.
17. Lin Y-L, Borenstein LA, Selvakumar R, et al. Effective vaccination against papilloma development by immunization with L1 or L2 structural proteins of cottontail rabbit papillomavirus. Virology 1992;187:612-9.
18. Christensen ND, Kreider JW, Kan NC, et al. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991;181:582-9.
19. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail papillomavirus can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
20. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci 1995;92:11553-7.
21. Chan S-Y, Ho L, Ong C-K, et al. Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol 1992;66:2057-66.
22. Jarrett WFH, Campo MS, O'Neil BW, et al. A novel bovine papillomavirus (BPV-6) causing true epithelial papillomas of the mammary gland skin: a member of a proposed new subgroup. Virology 1984;136:256-64.
23. Ford JN, Jennings PA, Spradbrow PB, et al. Evidence for papillomaviruses in ocular lesions in cattle. Res Vet Sci 1982;32:257-9.
24. Hill FWG, Klein WR, Hoyer MJ, et al. Antitumour effect of locally injected low-doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immun Immunopathol 1994;41:19-29.
25. Campo MS, O'Neil BW, Barron RJ, et al. Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in cattle. Carcinogenesis 1994;15:1597-601.
26. Campo MS, Jarrett WFH, Barron R, et al. Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. Cancer Res 1992;52:6898-904.
27. Jarrett WFH. The natural history of bovine papillomavirus infection. Adv Viral Onc 1985;5:83-102.
28. Olson C, Segre D, Skidmore LV. Further observations on immunity to bovine cutaneous papillomatosis. Am J Vet Res 1960;21:233-42.
29. Pilachinski WP, Glassman DL, Glassman KF, et al. Immunization against bovine papillomavirus infection. Ciba Found Sym 1986;120:136-49.
30. Jenson AB, Lim P, Ghim S, et al. Identification of linear epitopes of the BPV-1 L1 protein recognized by sera of infected or immunized animals. Pathobiology 1991;59: 396-103.
31. Gaukroger JM, Chandrachud LM, O'Neil BW, et al. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996;77:1577-83.
32. Knowles G, Chandrachud LM, O'Neil BW, et al. Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4. Res Vet Sci 1997 (in press).
33. Roden RBS, Weissinger EM, Henderson DW, et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol 1994;68:7570-7574.
34. Hagensee ME, Galloway DA. Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Rep 1993;4:121-4.
35. Hagensee ME, Olson NH, Baker TS, et al. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 1994;68:4503-5.
36. Rose RC, Bonnez W, Reichman RC, et al. Expression of human papillomavirus type 11 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J Virol 1993;67:1936-44.
37. Christensen ND, Kirnbauer R, Schiller JT, et al. Human papillomavirus type 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralising antibodies. Virology 1994;205:329-35.
38. Cohen J. Vaccines get a new twist. Science 1994;264:503-5.
39. Okabayashi M, Angell MG, Christensen ND, et al. Morphometric analysis and identification of infiltrating leucocytes in regressing and progressing Shope rabbit papillomas. Int J Cancer 1991;49:919-23.
40. Okabayashi M, Angell MG, Budgeon R, et al. Shope papilloma cell and leukocyte proliferation in regressing and progressing lesions. Am J Pathol 1993;142:489-96.
41. Coleman N, Birley HDL, Rentom AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-74.
42. Chandrachud LM, O'Neil BW, Jarrett WFH, et al. Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes. Virology 1994;200:98-104.
43. McGarvie GM, Grindlay GJ, Chandrachud LM, et al. T-cell responses to BPV-4 E7 during infection and mapping of T-cell epitopes. Virology 1995;206:504-10.
44. Tindle RW, Smith JA, Geysen HM, et al. Identification of B-epitopes in human papillomavirus type 16 E7 open reading frame protein. J Gen Virol 1990;71:1347-54.
45. Altmann A, Jochmus-Kudielka I, Frank R, et al. Definition of immunologenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur J Cancer 1992;28:326-33.
46. Meneguzzi G, Cerni C, Kieny MP, et al. Immunization against human papillomavirus type 16 tumour cells with recombinant vaccinia virus expressing E6 and E7. Virology 1991;181:62-9.
47. Chen L, Thomas EK, Hu S-L, et al. Human papillomavirus type 16 nucleoprotein E7 is a tumour rejection antigen. Proc Natl Acad Sci 1991;88:110-4.
48. McLean CS, Sterling JS, Mowat J, et al. Delayed type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. J Gen Virol 1993;74:239-45.
49. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol 1996;70:8451-8458.
50. Campo MS, Moar MH, Sartirana ML, et al. The presence of bovine papillomavirus type 4 DNA is not required for the progression to, or the maintenance of, the malignant state in cancers of the alimentary canal in cattle. EMBO J 1985;4:1819-25.
51. Schwartz E, Freese UK, Gissman L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-4.
52. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.